Pathology beyond neovascularization: New targets in age-related macular degeneration

Retina

Volumn 29, Issue SUPPL. 6, 2009, Pages

  Heier, Jeffrey S ^a  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

Author keywords

Atrophy; Exudative age related macular degeneration; Fibrosis; Integrins; Vascular disrupting agents

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VASCULAR TARGETING AGENT; VERY LATE ACTIVATION ANTIGEN 5;

ANTIANGIOGENIC ACTIVITY; ATROPHY; CONTROLLED STUDY; DRUG TARGETING; FIBROSIS; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NOTE; PATHOGENESIS; PATHOPHYSIOLOGY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ATROPHY; CHOROIDAL NEOVASCULARIZATION; FIBROSIS; HUMANS; MACULAR DEGENERATION; RADIOTHERAPY, ADJUVANT; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68049147293     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181ad26c1     Document Type: Note

References (4)

1. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
3. Klatt K, Zahn CG, Heier JS, Daniel P, Holz FG, Loeffler KU. Integrin a5b1in preretinal membranes associated with proliferative vitreoretinopathy (PVR). 2007 ARVO Annual meeting E-abstract, 1233.
4. Nieder C, Wiedenmann N, Andratschke NH, Astner ST, Molls M. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev Recent Clin Trials 2007;2:163-168. (Pubitemid 47554836)